New Brand Drug Pipeline
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Tramadol Oral Solution (Qdolo™) | Opioid Agonist | Pain | Launch pending. Approved September 1, 2020. |
| Oliceridine (Olinvyk™) Injection | Opioid Agonist | Pain | Launch anticipated following DEA assigning controlled substance schedule. Approved August 7, 2020. |
| Metoclopramide Nasal Spray (Gimoti™) | Gastrointestinal Agent | Gastroparesis | Launch anticipated Q4 2020. Approved June 19, 2020. |
| Celecoxib Oral Liquid (Elyxyb™) | NSAID | Migraine Headache Treatment | Launch pending. Approved May 5, 2020. |
| Benzhydrocodone HCl/ Acetaminophen (Apadaz™) |
Opioid Analgesic – Immediate Release |
Pain | Launch pending. Approved February 23, 2018. |
| Buprenorphine Depot Injection (Brixadi™) |
Opioid Agonist | Treatment of Opioid Addiction |
Anticipated approval December 1, 2020 following expiration of exclusivity period for Sublocade™. |
| Zolmitriptan (Qtrypta™) Patch | Migraine Agent | Migraine Headache Treatment | FDA review pending. |
| Celecoxib/Tramadol | NSAID/Opioid Agonist | Pain | FDA review pending. |
| Ansofaxine | Antidepressant | Major Depressive Disorder | FDA review anticipated December 2020. |
| Naloxone Injection (Zimhi™) | Opioid Antagonist | Opioid Overdose | FDA declined to approve November 2019. |
Generic Pipeline
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Apixaban (Eliquis®) | Anticoagulant | Treatment/Prophylaxis of Deep Vein Thrombosis | Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years. |
| Naloxone HCl (Narcan®) Nasal Spray |
Opioid Antidote | Opioid Overdose | Launch pending. Generic approved April 19, 2019. |
Available in the Last 12 Months
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Rimegepant (Nurtec™ ODT) | CGRP Antagonist | Migraine Headache Treatment | March 2020 |
| Ubrogepant (Ubrelvy™) | CGRP Antagonist | Migraine Headache Treatment | March 2020 |
| Lasmiditan (Reyvow™) | Migraine Agent | Migraine Headache Treatment | January 2020 |
Newly Available Generics
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Emtricitabine/Tenofovir (Truvada®) | Antiretroviral | HIV Post-Exposure Prophylaxis | October 2020 |
| Albuterol Sulfate (Proventil® HFA) | Inhaled Bronchodilator | Asthma | April 2020 |
| Naproxen/Esomeprazole (Vimovo®) | NSAID/GI Protectant | Pain/Stomach Ulcer Prophylaxis | February 2020 |
| Albuterol Sulfate (ProAir® HFA) | Inhaled Bronchodilator | Asthma | February 2020 |
| Hydrocodone Bitartrate (Zohydro® ER) | Opioid Analgesic – Extended Release | Pain | January 2020 |
| Doxepin (Silenor®) | Tricyclic Antidepressant | Sleep Disorders | January 2020 |
Discontinuations & Withdrawals
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Albuterol Sulfate | Inhaled Bronchodilator | Asthma | Perrigo Company recalled all lots of its generic September 2020 due to reports of clogged inhalers preventing accurate dosing. |
| Ranitidine (Zantac®) | H-2 Receptor Antagonist | Heartburn/Stomach Ulcer Prophylaxis | FDA asked all manufacturers to remove product from the market on April 1, 2020. |
| Morphine Sulfate/Naltrexone HCl (Embeda®) | Opioid Analgesic – Extended Release Abuse Deterrent | Pain | Stop sale date November 15, 2019 with anticipated unavailability early 2020. |